IBRX - ImmunityBio spikes after commercial update on lead drug Anktiva
2024-06-20 12:28:47 ET
More on ImmunityBio
- ImmunityBio: Anktiva's Launch Demands A Reassessment
- ImmunityBio: Anktiva Approval Opens Up A World Of Possibilities, Risks And Potential Gains
- ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications
- ImmunityBio, LadRx end licensing deal for cancer drug
- ImmunityBio immunotherapy shows positive overall survival in lung cancer trial